Last updated: August 3, 2026
ACEPHEN is a rectal acetaminophen suppository product positioned for patients who cannot take oral medication. Its core commercial value is route of administration rather than molecular differentiation. The current formulation strategy relies on a fatty suppository base, typically hydrogenated vegetable oil, to provide room-temperature integrity and melting or softening after rectal administration.[1]
The strongest opportunities are pediatric dosing, hospital use, perioperative care, hospice and palliative care, dysphagia, nausea and vomiting, and temporary use when oral or enteral administration is impractical. The principal constraints are weak product-level exclusivity, low switching costs, limited differentiation between generic suppliers, dose-stacking risks and the technical challenge of achieving reliable rectal drug release.
What is ACEPHEN and how is it formulated?
ACEPHEN is an acetaminophen rectal suppository. Public product labeling identifies acetaminophen as the active ingredient and a hydrogenated vegetable oil-type base as the inactive formulation component.[1]
| Attribute |
ACEPHEN profile |
| Active ingredient |
Acetaminophen, also called paracetamol |
| Dosage form |
Rectal suppository |
| Route |
Rectal |
| Common strengths |
120 mg, 325 mg and 650 mg presentations have been marketed under the ACEPHEN name |
| Primary excipient function |
Suppository base, structural support and drug-release vehicle |
| Pharmacologic category |
Non-opioid analgesic and antipyretic |
| Primary use case |
Patients unable to use oral or enteral acetaminophen |
| Product differentiation |
Route, strength, handling and supply reliability |
| Patent position |
Acetaminophen molecule and basic use are off-patent |
ACEPHEN’s excipient platform is commercially conventional. Hydrogenated vegetable oil provides a solid matrix that can be molded, packaged and transported without refrigeration under appropriate conditions. The base must soften or melt at rectal temperature while maintaining sufficient mechanical strength during storage and handling.
The formulation must control several competing properties:
- Suppository hardness during manufacturing, packaging and shipment.
- Softening and disintegration after administration.
- Uniform acetaminophen distribution throughout each unit.
- Limited sedimentation during molding.
- Acceptable rectal tolerability.
- Stability under temperature and humidity excursions.
- Clean release from the mold and primary package.
What excipients protect the commercial performance of ACEPHEN?
The excipient itself is unlikely to provide meaningful patent protection for a conventional ACEPHEN formulation. Its value is primarily technical and commercial. A well-selected base can improve manufacturing yield, dose uniformity, patient acceptability and shelf life.
Hydrogenated vegetable oil
Hydrogenated vegetable oil is the most direct excipient strategy for a conventional acetaminophen suppository. It has several advantages:
- It is familiar to suppository manufacturers.
- It provides a solid dosage form at ordinary room temperature.
- It can be processed through melt molding.
- It has a relatively straightforward regulatory history.
- It supports a simple label with limited excipient complexity.
Its main technical limitations are polymorphism, variable melting behavior and potential release variability. Changes in cooling rate, storage temperature or oil composition can alter crystal structure and hardness. These changes can affect dissolution and drug release even when the nominal composition remains unchanged.
Polyethylene glycol bases
Polyethylene glycol, or PEG, can produce a firmer suppository with lower dependence on melting at body temperature. PEG systems dissolve in rectal fluid rather than simply melting. They can improve physical stability in warm climates and may reduce the risk of softening during distribution.
The disadvantages include possible rectal irritation, hygroscopicity, slower dissolution for certain grades and greater sensitivity to PEG molecular-weight selection. A PEG-based ACEPHEN competitor would need comparative release, tolerability and stability data.
Fatty glyceride systems
Semi-synthetic glycerides and hard-fat systems can provide more predictable melting behavior than some vegetable-oil bases. They also permit formulation tuning through combinations of low-, medium- and high-melting fractions.
The commercial advantage is process control. The disadvantage is that the formulation can become more complex, with additional raw-material qualification and greater need for control of polymorphism and thermal history.
Surfactants and wetting agents
Small quantities of surfactants may improve wetting and acetaminophen dispersion, particularly because acetaminophen has limited aqueous solubility. The tradeoff is increased risk of irritation, softening, migration or instability. Surfactants should be used only when dissolution or content-uniformity data show a clear benefit.
How should a manufacturer optimize the ACEPHEN excipient platform?
A commercially credible development program should begin with the existing hydrogenated vegetable oil platform as the reference formulation. The goal should be a measurable improvement rather than a cosmetic excipient substitution.
Priority formulation targets
| Target |
Relevant test |
| Mechanical strength |
Breaking force, deformation and drop testing |
| Thermal robustness |
Softening or melting range and temperature-excursion studies |
| Drug release |
Dissolution or in vitro release under validated conditions |
| Dose uniformity |
Assay and content uniformity across beginning, middle and end of molding runs |
| Physical stability |
Shape, cracking, sweating, blooming and leakage |
| Patient handling |
Ease of removal from packaging and insertion |
| Rectal tolerability |
Irritation and local tolerability assessment |
| Shelf life |
Accelerated and long-term stability |
| Manufacturing efficiency |
Molding yield, cycle time and reject rate |
The best near-term opportunity is a formulation that retains the familiar fatty base but improves heat resistance, dose uniformity or release consistency. This approach lowers regulatory and manufacturing risk compared with a completely different delivery system.
A second opportunity is a high-temperature-stable version for tropical and decentralized markets. Packaging and base selection should be developed together. A superior base can lose its commercial value if the blister or strip package permits deformation, oil migration or seal failure.
What formulations are protected by ACEPHEN patents?
No meaningful product-level patent moat is apparent for the basic acetaminophen suppository concept. Acetaminophen is a long-established small molecule, and conventional rectal dosage forms are generally exposed to generic competition.
| IP category |
Likely position for conventional ACEPHEN |
| Acetaminophen composition of matter |
Expired or unavailable as a new-molecule barrier |
| Basic rectal suppository concept |
Broadly vulnerable to prior art |
| Hydrogenated vegetable oil base |
Usually difficult to protect broadly |
| Specific excipient ratio |
Potentially protectable, but narrow and design-around risk is high |
| Manufacturing process |
Potentially protectable if technically distinctive |
| Packaging system |
Potentially protectable if it solves a specific stability or handling problem |
| Controlled-release rectal delivery |
Potentially patentable, but development and regulatory requirements increase |
| Method of use |
Potentially protectable only for a differentiated, supportable clinical use |
A new entrant could seek patent protection for a narrowly defined formulation containing specific base components, particle-size parameters, release characteristics, thermal properties or manufacturing conditions. Such claims would face validity and obviousness challenges if the formulation is a routine optimization of known suppository technologies.
The strongest defensible IP would likely combine:
- A defined excipient composition.
- A measurable release profile.
- A specified melting or softening range.
- A manufacturing process that produces a critical microstructure.
- Packaging that preserves the formulation under defined temperature excursions.
Trade-secret protection may be more practical for process parameters, cooling profiles, filling conditions and in-process controls than broad formulation patents.
When does ACEPHEN lose exclusivity?
ACEPHEN does not appear to rely on a current new-chemical-entity exclusivity period. Acetaminophen has been marketed for decades, and the basic product concept is open to generic competition.
The relevant commercial protections are therefore:
- Any current product-specific regulatory exclusivity, if applicable.
- Active patents listed for a particular product.
- Manufacturing scale and supply reliability.
- Institutional contracts.
- Brand recognition among hospitals, pharmacies and caregivers.
- Formulation or packaging differentiation.
The absence of a strong patent barrier does not guarantee immediate generic entry. Rectal dosage forms can have smaller markets, more difficult manufacturing economics and less predictable pharmacy demand than oral tablets or liquids. These factors can reduce the number of active competitors.
What is the FDA regulatory status of ACEPHEN?
ACEPHEN is a drug product containing acetaminophen in a rectal dosage form. FDA regulatory analysis should distinguish the marketed label, the product’s application pathway and any current Orange Book listing.[1][2]
A manufacturer seeking to commercialize a comparable product may evaluate:
- An abbreviated new drug application if a suitable reference product and bioequivalence pathway are available.
- A 505(b)(2) application if the product relies on published literature or an approved product but introduces meaningful formulation or dosage-form differences.
- A full new drug application if the product cannot rely on an established reference or recognized bridging approach.
Rectal acetaminophen presents a more complicated bioequivalence question than an immediate-release oral tablet. Local release, rectal absorption, suppository melting, dose recovery and systemic exposure can all affect comparability. A formulation that changes the base or release mechanism may require more extensive clinical or pharmacokinetic support.
What generic entry risks exist for ACEPHEN?
Generic entry risk is structurally high but commercially moderated by market size.
High-risk factors for the incumbent
- No meaningful composition-of-matter protection.
- Simple active ingredient.
- Conventional excipient platform.
- Multiple possible fatty and PEG-based alternatives.
- Low switching costs for pharmacies and hospitals.
- Potential for private-label or contract-manufactured products.
Factors that can delay or reduce entry
- Small and fragmented demand.
- Limited manufacturing capacity for suppositories.
- Product-specific stability and packaging requirements.
- Difficulty achieving consistent dissolution and content uniformity.
- Hospital purchasing contracts.
- Regulatory complexity for demonstrating equivalence.
- Supply-chain requirements for multiple strengths.
The principal generic launch scenario is a conventional acetaminophen suppository with the same strengths and a comparable fatty base. A second scenario is a private-label product supplied through a contract manufacturer. A third is a differentiated product with improved heat stability or a broader pediatric strength range.
Which companies are challenging ACEPHEN?
Publicly available product information does not establish a single dominant Paragraph IV challenger to ACEPHEN. The competitive threat is more likely to come from generic acetaminophen suppository suppliers, private-label manufacturers and institutional distributors than from a high-profile patent challenge.
Because the core technology is mature, a competitor may not need to challenge a patent. It can develop a non-infringing formulation and pursue its own regulatory filing. Paragraph IV litigation is therefore less central than ordinary ANDA competition unless an incumbent obtains and lists a narrow formulation or process patent.
What commercial opportunities exist for ACEPHEN excipient innovation?
Pediatric dosing
Pediatric rectal dosing is a significant opportunity where oral administration is difficult. Smaller strengths can support weight-based dosing and reduce tablet splitting or liquid-measuring errors. The commercial risk is that pediatric acetaminophen use requires clear dosing instructions and strong controls against duplicate administration from multiple acetaminophen-containing products.
A product line could include:
- Low-dose pediatric suppositories.
- Intermediate strengths for school-age children.
- Adult strengths for hospitals and home care.
- Weight-based dosing charts supported by labeling and packaging.
Hospital and perioperative care
Hospitals use rectal administration when patients are NPO, sedated, vomiting or unable to swallow. A formulation with reliable insertion, rapid softening and consistent exposure could compete on procurement criteria rather than consumer branding.
Relevant commercial claims must remain within approved labeling and supported evidence. Hospitals are likely to value:
- Unit-dose packaging.
- Barcode compatibility.
- Clear strength differentiation.
- Low breakage and leakage.
- Room-temperature stability.
- Reliable supply.
- Reduced nursing preparation time.
Hospice and palliative care
Rectal delivery can be useful when swallowing is impaired. A low-irritation base and easy-open packaging may have more practical value than a novel release profile. The product should prioritize administration simplicity, storage flexibility and clear dose accounting.
Tropical and decentralized markets
Heat-stable formulations and robust packaging can support distribution in regions where refrigeration is unavailable. A base with improved thermal resistance may create commercial value if it preserves dosage-form integrity through transportation and storage.
Combination or co-pack strategies
The most realistic combination opportunity may be a co-pack or care pathway rather than a new combination drug. Examples include acetaminophen suppositories supplied with dosing aids, institutional administration instructions or pediatric weight-based packaging. Any combination product containing another active ingredient would face higher regulatory, safety and manufacturing complexity.
How does ACEPHEN compare with oral acetaminophen products?
| Criterion |
ACEPHEN suppository |
Oral tablet or liquid |
| Administration |
Rectal |
Oral |
| Use in vomiting or dysphagia |
Advantage |
Limited |
| Dose flexibility |
Moderate, dependent on available strengths |
High, especially liquids |
| Absorption predictability |
More variable |
Generally more predictable |
| Patient acceptance |
Often lower |
Usually higher |
| Manufacturing complexity |
Higher |
Lower |
| Distribution cost |
Higher per dose |
Lower per dose |
| Differentiation potential |
Route, base, packaging and strength |
Taste, release profile and combination use |
| Generic competition |
Moderate in number, but technically specialized |
Intense |
| Institutional value |
High in selected settings |
Broad but less specialized |
ACEPHEN should not be positioned as a general replacement for oral acetaminophen. Its strongest value is as a route-specific product for defined clinical situations.
What patent and licensing strategy is commercially viable?
A broad patent on "acetaminophen in a suppository" would face substantial prior-art risk. A viable strategy would focus on a narrower technical problem with objective performance data.
Potential claims could cover:
- A specific hydrogenated-oil blend with a defined melting range.
- Improved acetaminophen suspension stability during molding.
- A release profile linked to a defined base composition.
- A low-irritation formulation for repeated rectal administration.
- A heat-resistant package and suppository combination.
- A manufacturing process that improves content uniformity.
Licensing opportunities are more likely to involve excipient technology, formulation know-how, packaging systems or contract manufacturing than rights to acetaminophen itself. A company with validated suppository manufacturing capacity could license a base technology to a branded or private-label marketer.
Key Takeaways
- ACEPHEN is a route-differentiated acetaminophen suppository, not a molecule protected by modern exclusivity.
- Hydrogenated vegetable oil is the logical baseline excipient platform.
- The strongest formulation opportunities involve thermal stability, dose uniformity, release consistency, packaging and tolerability.
- Generic entry risk is high because the active ingredient and basic dosage-form concept are mature.
- Commercial demand is concentrated in pediatrics, hospitals, perioperative care, hospice, dysphagia and vomiting.
- Paragraph IV litigation is less likely to define the market than ordinary generic and private-label competition.
- Narrow formulation, process and packaging patents are more credible than broad suppository claims.
- Manufacturing reliability, institutional contracting and distribution quality may create more value than brand promotion.
FAQs
Can ACEPHEN be reformulated with PEG instead of hydrogenated vegetable oil?
Yes, but the change would require comparative evaluation of dissolution, release, rectal tolerability, stability, melting or dissolution behavior and regulatory comparability. PEG may improve heat stability while increasing irritation or hygroscopicity risks.
Is the ACEPHEN suppository base likely to be patentable?
A conventional base is unlikely to support broad enforceable protection. Patentability improves if the base produces a demonstrated and non-obvious technical result, such as improved content uniformity, heat resistance or release performance.
What is the best commercial strength for a new ACEPHEN competitor?
The answer depends on the target segment. Pediatric strengths support outpatient and caregiver use, while 325 mg and 650 mg strengths are more relevant to adult and hospital demand. A multi-strength portfolio reduces substitution risk.
Can a new acetaminophen suppository use the same excipients as ACEPHEN?
Potentially, provided the formulation does not infringe an active formulation or process patent and meets applicable regulatory requirements. Excipients that are common in the dosage form generally provide limited standalone differentiation.
Does a new ACEPHEN product require a Paragraph IV certification?
Only if the relevant application references listed patents and the applicant seeks approval before their expiration while asserting that the patents are invalid, unenforceable or not infringed. A new product may instead avoid listed claims or enter after expiration.
References
- U.S. National Library of Medicine. (n.d.). DailyMed: ACEPHEN acetaminophen suppository labeling. National Library of Medicine.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
- U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA.
- United States Pharmacopeia. (2023). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.
